Michelle Dawson posts

Post published on Twitter/X on 8 Mar 2023 13:52

Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Elizabeth Austen Lawson, United States Department of Defense, University of Virginia (2023). Oxytocin Effects on Bone in Children With Autism Spectrum Disorder. ClinicalTrials.gov. Elizabeth Austen Lawson.

Publication date
1 Aug 2023
Identifier
NCT05754073
Authors
Elizabeth Austen Lawson, United States Department of Defense, University of Virginia
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Elizabeth Austen Lawson
Metadata source
clinicaltrials.gov

Abstract

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin on bone health in children with autism spectrum disorder, ages 6-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (30 IU, 2 times daily) for 12 months in the double-blind phase, followed by a 6-month open label phase during which all study subjects will receive intranasal oxytocin (30 IU, 2 times daily). Study visits include screening to determine eligibility, followed by study visits at baseline, week 2, and months 6, 12, 18 and phone calls every two weeks for the first two months and monthly thereafter for the duration of the study. Study assessments include history and physical examinations, anthropometric measurements, electrocardiogram (EKG), adverse event monitoring, laboratory tests for chemistries, hormones and biomarkers for bone metabolism, questionnaires regarding diet and exercise, and imaging to assess body composition, bone density and structure.